Brought to you by 
AstraZeneca buys Almirall's respiratory franchise for $875mm plus earn-outs
31 Jul 2014
Executive Summary
AstraZeneca PLC paid $875mm to buy Spanish drug-maker Almirall SA’s respiratory business, which contains one marketed therapy along with others in development. Almirall could get up to $1.22bn in development, launch, and sales-related earn-outs, plus additional undefined sales-related payments.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys Almirall's respiratory franchise for $875mm plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice